Search

Your search keyword '"Samuel Chi-Hang Yee"' showing total 2 results
Start Over Author "Samuel Chi-Hang Yee" Search Limiters Available in Library Collection
2 results on '"Samuel Chi-Hang Yee"'

1. A prospective cohort of men with localized prostate cancer on active surveillance protocol in Hong Kong, China: what did we learn?

Author

Xiaobo Wu, Ivan Ching-Ho Ko, Cindy Yeuk-Lam Hong, Samuel Chi-Hang Yee, Jeremy Yuen-Chun Teoh, Samson Yun-Sang Chan, Ho-Man Tam, Chi-Kwok Chan, Chi-Fai Ng, and Peter Ka-Fung Chiu

Subjects
active surveillance, cohort, localized, prostate cancer, Diseases of the genitourinary system. Urology, RC870-923
Abstract

This study aimed to report the outcomes of active surveillance (AS) in the management of low-risk prostate cancer (PCa). It recruited 87 men who were prospectively followed up according to the Prostate Cancer Research International Active Surveillance (PRIAS) protocol with local adaptation at SH Ho Urology Centre, Prince of Wales Hospital, Hong Kong, China. We investigated the predictors of disease progression and found that baseline prostate-specific antigen density (PSAD) and the presence of the highest Prostate Imaging-Reporting and Data System (PI-RADS) score 5 lesion on magnetic resonance imaging (MRI) are significantly correlated with disease progression. Moreover, men with PSAD >0.2 ng ml−2 or PI-RADS 4 or 5 lesions had significantly worse upgrading-free survival compared to those with PSAD ≤0.2 ng ml−2 and PI-RADS 2 or 3 lesions. The study concludes that AS is a safe and effective management strategy for selected patients to defer radical treatment and that most disease progression can be detected after the first repeated biopsy. The combination of PSAD >0.2 ng ml−2 and PI-RADS 4 or 5 lesions may serve as a useful predictor of early disease progression and provide a guide to optimize follow-up protocols for men in different risk groups.

Published
2024
Full Text
View/download PDF

2. Hemopatch to Prevent Lymphatic Leak after Robotic Prostatectomy and Pelvic Lymph Node Dissection: A Randomized Controlled Trial

Author

Jeremy Yuen-Chun Teoh, Alex Qinyang Liu, Violet Wai-Fan Yuen, Franco Pui-Tak Lai, Steffi Kar-Kei Yuen, Samson Yun-Sang Chan, Julius Ho-Fai Wong, Joseph Kai-Man Li, Mandy Ho-Man Tam, Peter Ka-Fung Chiu, Samuel Chi-Hang Yee, and Chi-Fai Ng

Subjects
Cancer Research, Oncology, Hemopatch, prostate cancer, prostatectomy, pelvic lymph node dissection, lymphatic leak
Abstract

This study investigates whether the application of Hemopatch, a novel hemostatic patch, could prevent lymphatic leak after robotic-assisted radical prostatectomy (RARP) and bilateral pelvic lymph node dissection (BPLND). This is a prospective, single-center, phase III randomized controlled trial investigating the efficacy of Hemopatch in preventing lymphatic leak after RARP and BPLND. Participants were randomized to receive RARP and BPLND, with or without the use of Hemopatch, with an allocation ratio of 1:1. The primary outcome is the total drain output volume. The secondary outcomes include blood loss, operative time, lymph node yield, duration of drainage, drain output per day, hospital stay, transfusion and 30-day complications. A total of 32 patients were recruited in the study. The Hemopatch group had a significantly lower median total drain output than the control group (35 mL vs. 180 mL, p = 0.022) and a significantly lower drain output volume per day compared to the control group (35 mL/day vs. 89 mL/day, p = 0.038). There was no significant difference in the other secondary outcomes. In conclusion, the application of Hemopatch in RARP and BPLND could reduce the total drain output volume and the drain output volume per day. The use of Hemopatch should be considered to prevent lymphatic leakage after RARP and BPLND.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results